A review of the aldosterone antagonist spironolactone is presented. It is effective both as monotherapy and in combination with other hypotensive agents in the control of both essential and hyperaldosterone-induced hypertension. It is useful as a diuretic in conditions such as cirrhosis and congestive heart failure, and is most commonly employed because of its potassium- and magnesium-sparing qualities. Spironolactone also has been used as an antiandrogenic agent in managing hirsutism. Its adverse effect profile, considered somewhat prohibitive in the past, is generally not significant when reasonably low doses (<150 mg/d) are used.
Get full access to this article
View all access options for this article.
References
1.
GREENBLATTDJ, KOCH-WESERJ.Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program.JAMA1973; 225: 40–3.
2.
LOUBESD, QUIRKRA. Breast cancer associated with administration of spironolactone.Lancet1975; 1: 1428–9.
3.
HOLLIFIELDJW, SLATONPE. Thiazide diuretics, hypokalemia and cardiac arrhythmias.Acta Med Scand1981; 647(suppl): 67–73.
4.
DYCKNERT, WESTERPO. Potassium-sparing diuretics.Acta Med Scand1986; 707(suppl): 79–83.
5.
GUMSJG. Clinical significance of magnesium: a review.Drug Intell Clin Pharm1987; 21: 240–6.
6.
BEEVERSDG, BROWNJJ, FERRISSJB, FRASERR, LEVERAF, ROBERTSONJIS. The use of spironolactone in the diagnosis and treatment of hypertension with mineralocorticoid excess.Am Heart J1973; 86: 404–14.
7.
DYCKNERT, WESTERPO, WIDMANL.Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension.Eur J Clin Pharmacol1986; 30: 535–40.
CORVOLP, CLAIREM, OBLINME, GEERINGK, ROSSIERB.Mechanism of the antimineralocorticoid effects of spironolactones.Kidney Int1981; 20: 1–6.
10.
WEINERIM. General pharmacological aspects of diuretics. In: DirksJH, SuttonRAL eds. Diuretics: physiology, pharmacology, and clinical use.Philadelphia: WB Saunders, 1986: 3–28.
11.
SADEEW, DAGCIOGLUM, SCHRODERR.Pharamocokinetics of spironolactone, canrenone and canrenoate-K in humans.J Pharmacol Exp Ther1973; 185: 686–95.
12.
SMITHAGE. Spironolactone in the long-term management of patients with congestive heart failure.Curr Med Res Opin1980; 7: 131–6.
13.
SETTELE.Further experience with spironolactone-hydrochlorothiazide (Aldactazide-A) in the long-term treatment of refractory cardiac edema.J Am Geriatr Soc1965; 13: 655–62.
14.
IKRAMH, WEBSTERMWI, NICHOLLSMG, LEWISGRJ, RICHARDSAM, CROZIERIG. Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure.Aust N Z J Med1986; 16: 61–3.
15.
SCHERSTENB, THULINT, KUYLENSTIERNAJClinical and biochemical effects of spironolactone administered once daily in primary hypertension.Hypertension1980; 2: 672–9.
16.
BERGLUNDG, ANDERSSONO.Hydrochlorothiazide and spironolactone alone and in a fixed combination in hypertension.Curr Ther Res1980; 27: 360–4.
17.
AKBARFA, BOSTONPF, CHAPMANJ, PEARCEMY. Spironolactone and hydroflumethiazide in the treatment of hypertension.Br J Clin Pract1981; 35: 317–21.
18.
HOEFNAGELSWHL, DRAYERJIM, SMALSAGH, KLOPPENBURGPWC. Spironolactone and amiloride in hypertensive patients with and without aldosterone excess.Clin Pharmacol Ther1980; 27: 317–23.
19.
SPARKRF, MELBYJC. Aldosteronism in hypertension: the spironolactone response test.Ann Intern Med1968; 69: 685–91.
20.
WOLFRL, MENDLOWITZM, ROBOZJ, STYANGPH, KORNFELDP, WEIGLA.Treatment of hypertension with spironolactone.JAMA1966; 198: 1143–9.
21.
JEUNEMAITREX, CHATELLIERG, KREFT-JAISC,Efficacy and tolerance of spironolactone in essential hypertension.Am J Cardiol1987; 60: 820–5.
22.
CRANEMG, HARRISJJ. Effect of spironolactone in hypertensive patients.Am J Med Sci1970; 260: 311–30.
23.
WINERBM, LUBBEWF, COLTONT.Antihypertensive actions of diuretics: comparative study of an aldosterone antagonist and a thiazide, alone and together.JAMA1968; 204: 775–9.
24.
AKBARFA, PEARCEMY. Spironolactone and propranolol in the management of hypertension.Br J Clin Pract1984; 38: 110–4.
25.
LAVENIUSB, HARRISONL.A double-blind comparison of spironolactone and hydrochlorothiazide in hypertensive patients treated with metoprolol.Int J Clin Pharmacol Ther Toxicol1982; 20: 291–5.
26.
BRESTAN. Spironolactone in the treatment of hypertension: a review.Clin Ther1986; 8: 568–85.
27.
PEREZ-STABLEE, CARALISPV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism.Am Heart J1983; 106: 245–51.
28.
FAGERBERGSE. Serum lipids and some metabolic parameters after treatment with spironolactone and thiazides in hypertensive patients.Curr Ther Res1982; 32: 872–8.
29.
AMESRP. The effects of antihypertensive drugs on serum lipids and lipoproteins: I. diuretics.Drugs1986; 32: 260–78.
30.
AMESRP, HILLP.Elevation of serum lipid levels during diuretic therapy of hypertension.Am J Med1976; 61: 748–57.
SCHAMBELANM, BRUSTN, CHANGB, BIGLIERIEG. Aldosterone production in low renin hypertensive states: response to spironolactone therapy. In: SambhiMP, ed. International Workshop Conference on Mechanisms; of Hypertension.New York: Elsevier, 1973: 187–92.
33.
CONNJW. Primary aldosteronism and primary reninism.Hosp Pract1974; 9: 131–40.
34.
CONNJW. Primary aldosteronism: a new clinical syndrome.J Lab Clin Med1955; 45: 3–17.
35.
BROWNJJ, DAVIESDL, FERRISSJBComparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess and low plasma renin.Br Med J1972, 2: 129–34.
36.
MULLERJ.Spironolactone in the management of congestive cardiac failure: a review.Clin Ther1986; 9: 63–76.
MITCHELLK, POWELLLW. Management of the patient with ascites.Drugs1980; 19: 383–7.
39.
FRAKESJT. Physiologic considerations in the medical management of ascites.Arch Intern Med1980; 140: 620–3.
40.
EGGERTRC. Spironolactone diuresis in patients with cirrhosis and ascites.Br Med J1970; 4: 401–3.
41.
WHEELERPG, SMITHT, GOLINDANOCPotassium and magnesium depletion in patients with cirrhosis on maintenance diuretic regimens.Gut1977; 18: 683–7.
42.
SOLERNG, JAINS, JAMESH, PATONA.Potassium status of patients with cirrhosis.Gut1976; 17: 152–7.
43.
VESINP.Potassium metabolism and diuretics administration in liver cirrhosis.Postgrad Med J1975; 51: 545–8.
44.
STEINESSE.Diuretics, digitalis, and arrhythmias.Acta Med Scand1981; 647(suppl): 75–8.
45.
JACKSONPR, RAMSAYLE, WAKEFIELDV.Relative potency of spironolactone, triamterene, and potassium chloride in thiazide-induced hypokalemia.Br J Clin Pharmacol1982; 14: 257–63.
46.
GEORGECF, BRECKENRIDGEAM, DOLLERYCT. Comparison of the potassium-retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalemia.Lancet1973; 2: 1288–91.
47.
RAMSAYLE, HETTIARACHCHIJ, FRASERR, MORTONJJ. Amiloride, spironolactone and potassium chloride in thiazide-treated hypertensive patients.Clin Pharmacol Ther1980; 27: 533–43.
DYCKNERT, WESTERPO. Intracellular magnesium loss after duretic administration.Drugs1984; 28(suppl 1): 161–6.
50.
CUMMINGDC, YANGJC, REBARRW, YENSSC. Treatment of hirsutism with spironolactone.JAMA1982; 247: 1295–8.
51.
CHAPMANMG, KATZM, DOWSETTM, HAGUEW, JEFFCOATESL, DEWHURSTCJ. Spironolactone in the treatment of hirsutism.Acta Obstet Gynecol Scand1986; 65: 349–50.
52.
MUHLEMANNMF, CARTERGD, CREAMJJ, WISEP.Oral spironolactone: an effective treatment for acne vulgaris in women.Br J Derm1986; 115: 227–32.
53.
CHAPMANMG, DOWSETTM, DEWHURSTCJ, JEFFCOATESL. Spironolactone in combination with an Oral contraceptive: an alternative treatment for hirsutism.Br J Obstet Gynecol1985; 92: 983–5.
54.
HUFFMANDH, KAMPMANNJP, HIGNITECE, AZARNOFFDL. Gynecomastia induced in normal males by spironolactone.Clin Pharmacol Ther1978; 24: 465–73.
55.
NUTTALLFQ. Gynecomastia as a physical finding in normal men.J Clin Endocrinol Metab1979; 48: 338–40.
